The inflection point of the traditional Chinese medicine industry has come, and the Nuggets have 3 sub-tracks

[Pharmaceutical Network Market Analysis] In recent years, with the establishment and improvement of industry standards, mechanisms and service systems, the traditional Chinese medicine industry has gradually presented a good situation of equal emphasis on traditional Chinese and Western medicine, support and regulation, inheritance and innovation.
high-quality development stage
.

The industry said that they are optimistic about the three sub-tracks of the traditional Chinese medicine industry
.

Proprietary Chinese patent medicines highlight the advantages of leading OTC companies.
Chinese patent medicines refer to medicines that use medicinal materials as raw materials according to the theory of traditional Chinese medicine, and make certain dosage forms according to prescribed prescriptions and processes for doctors to prescribe or patients to purchase
.

OTC proprietary Chinese medicines have independent pricing power.
With the rising prices of upstream Chinese herbal medicines and the increased acceptance of downstream pharmacies, OTC price increases channels for proprietary Chinese medicines have been smooth in recent years, which is expected to increase profits
.

In addition, with the improvement of consumer brand awareness and the increase of online channel share, the growth of top brands continued to exceed the industry average
.

Statistics show that from 2005 to 2021, Pien Tze Huang has raised the price 11 times, from 125 yuan to 590 yuan; Tongrentang's Angong Niuhuang Pill has raised the price three times, from 350 yuan to 860 yuan
.

From 2015 to the present, the gross profit margin of the top Chinese patent medicine OTC companies has been steadily increasing.
It has not been significantly affected by the increase in the price of upstream Chinese herbal medicines, the control of medical insurance costs, and the improvement of drug quality standards, reflecting strong cost and quality control capabilities.
and terminal premium capability
.

Analysts said that the OTC of branded Chinese patent medicines benefited from the clearing of the industry's production capacity and the increase in terminal prices
.

It is recommended to pay attention to brand Chinese patent medicine companies such as Tongrentang, Pien Tze Huang, Tai Chi Group, Zhongxin Pharmaceutical, Lingrui Pharmaceutical, Yiling Pharmaceutical, Jianmin Group, and Yunnan Baiyao
.

 　　On November 1, 2021, the traditional Chinese medicine formula granules completed the pilot work of more than 20 years, and were included in the management of traditional Chinese medicine pieces, and the filing system was officially implemented
.

Since then, the production of traditional Chinese medicine formula granules has been opened to qualified enterprises other than provincial pilot enterprises, and enterprises are allowed to sell across provinces after filing
.

 　　Analysts said that the pilot program of traditional Chinese medicine formula granules has ended, and the tens of billions market will be expanded by 1-2 times.
The filing system and the new national standard will build high industry barriers
.

 　　According to data from the Ministry of Industry and Information Technology, from 2019 to 2020, the market size of traditional Chinese medicine formula granules is about 50.
3 billion yuan and 53.
3 billion yuan respectively
.

It is predicted that with the completion of the pilot work and the continuous introduction of new policies, the competitive environment will begin to change, and more companies will enter the game in the future
.

In addition, data show that nearly 80 companies across the country have previously obtained the pilot qualification for traditional Chinese medicine formula granules
.

It is estimated that the future industry market size may exceed 100 billion
.

 　　In order to promote the healthy development of the traditional Chinese medicine formula granule industry, it is suggested in the industry to encourage enterprises to make one or several kinds of traditional Chinese medicine formula granule products that they are good at
.

At the same time, promote the implementation of centralized procurement of traditional Chinese medicine formula granules, so that a single variety can enter the centralized procurement, give full play to the professional competitive advantage, and promote the healthy development of traditional Chinese medicine formula granules
.

 　　For the development of traditional Chinese medicine formula granules, the industry recommends paying attention to China Traditional Chinese Medicine (H) (the parent company of Taiji Group), Hongri Pharmaceutical, China Resources Sanjiu,
etc.

 　　The pace of registration and review has accelerated, and the inflection point of new Chinese medicines has reached the historical data show that in 2017, the approval of a new Chinese medicine drug even took 3,600 days.
Batch listing, time-to-market shortened by 90%
.

It is worth noting that the new anti-cancer drug icariin soft capsules, which will be approved for marketing in 2022, will be approved for marketing in less than 300 days
.

 　　According to the industry, the pace of registration and review has accelerated, and the inflection point of new Chinese medicine drugs has come.
In the future, the speed of approval and listing of new Chinese medicine drugs may be further shortened
.

According to the data, the innovation trend of traditional Chinese medicine is performing well
.

For example, in 2021, the proportion of clinical applications for innovative traditional Chinese medicine drugs will account for 65%, which is twice that of 2020 and about five times that of 2019
.

In 2021, the State Food and Drug Administration has approved a total of 12 new Chinese medicines, which is four times the number in 2020.
The number of new Chinese medicines approved in 2021 accounts for 54% of the total number of new Chinese medicines approved in the past five years
.

 　　Some institutions predict that the approval and marketing of new Chinese medicines will be accelerated in the future, and the number of new Chinese medicines listed on the market may exceed 20 each year
.

In addition, some institutions also pointed out that the policy encourages the innovative traditional Chinese medicine sector.
Under the background of standardized review and approval, the number of innovative traditional Chinese medicines on the market will grow steadily
.

 　　In addition, in terms of market access for new traditional Chinese medicines, the National Medical Insurance Drug Catalog has been continuously included in traditional Chinese medicine varieties in the previous revisions, and the number of varieties of traditional Chinese medicines and Western medicines is basically equal, which will also promote the development of new traditional Chinese medicines
.

 　　As the policy clears the way from the research and development side, encourages and accelerates the research and development, review and approval of new traditional Chinese medicine drugs, as well as the normalized national medical insurance negotiation and relaxation of cost control, accelerates the realization of the clinical value and commercial value of new traditional Chinese medicine drugs, and promotes the sustainable development of the industry In the future, new traditional Chinese medicine drugs may be a feasible way for the innovation and development of the pharmaceutical industry
.

 　　For new traditional Chinese medicine drugs, the industry recommends paying attention to Kangyuan Pharmaceuticals, Yiling Pharmaceuticals, Tasly, Fangsheng Pharmaceuticals, Xintian Pharmaceuticals, etc.
, which are strong in R&D of new Chinese medicines
.

 　　Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.